IP Library Patent Application 13249248
Patent Application
App. No. 13/249,248

Method of treating osteoporosis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/249,248
Abstract

A method for treating osteoporosis and related methods are disclosed. The methods generally comprise administering to a patient in need of treatment an effective amount of tris(8-quinolinolato)gallium(III) or an analog thereof.

Claims (14)

1 . A method of reducing osteoclastic bone resorption in a patient, comprising administering to the patient an effective amount of a compound according to Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

2 . A method of treating or preventing osteoporosis, comprising administering to a patient in need of treatment an effective amount of a compound according to Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

3 . A method of treating or preventing or reducing the risk of low bone mineral density, bone loss, skeletal-related events including bone fractures, or increasing bone mass, comprising administering to a patient in need of treatment an effective amount of a compound according to Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

4 . A method of treating or delaying the onset of localized bone loss associated with periodontal diseases or with periprosthetic osteolysis, comprising administering to a patient an effective amount of a compound according to Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

5 . A method of treating or preventing Paget's disease, comprising administering to a patient in need of treatment an effective amount of a compound of Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

6 . A method for preventing, or delaying the onset of, bone metastasis of cancer in a patient, comprising administering to the patient an effective amount of a compound of Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

7 . A method of treating a cancer metastasized to bone, comprising administering to a patient having a cancer with bone metastasis an effective amount of a compound of Formula (I)

wherein R 1 represents hydrogen, a halogen or a sulfono group SO 3 M, in which M is a metal ion, and R 2 represents hydrogen, or R 1 is Cl and R 2 is I, or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: NIIKI PHARMA INC.
To: NIIKI PHARMA AQUISITION CORP. 2
Reel/Frame 030740/0100 →